DK3303329T3 - Fremgangsmåder til fremstilling af indazolderivater - Google Patents

Fremgangsmåder til fremstilling af indazolderivater Download PDF

Info

Publication number
DK3303329T3
DK3303329T3 DK16726309T DK16726309T DK3303329T3 DK 3303329 T3 DK3303329 T3 DK 3303329T3 DK 16726309 T DK16726309 T DK 16726309T DK 16726309 T DK16726309 T DK 16726309T DK 3303329 T3 DK3303329 T3 DK 3303329T3
Authority
DK
Denmark
Prior art keywords
indazold
procedures
derivatives
preparing
preparing indazold
Prior art date
Application number
DK16726309T
Other languages
English (en)
Inventor
Robert Nicholas Bream
John David Hayler
Alan Geoffrey Ironmonger
Peter Szeto
Michael Robert Webb
Katherine Marie Penelope Wheelhouse
Robert David Willacy
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Application granted granted Critical
Publication of DK3303329T3 publication Critical patent/DK3303329T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
DK16726309T 2015-06-02 2016-05-31 Fremgangsmåder til fremstilling af indazolderivater DK3303329T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1509492.3A GB201509492D0 (en) 2015-06-02 2015-06-02 Novel processes
PCT/EP2016/062250 WO2016193255A1 (en) 2015-06-02 2016-05-31 Processes to make indazole derivatives

Publications (1)

Publication Number Publication Date
DK3303329T3 true DK3303329T3 (da) 2019-12-02

Family

ID=53677608

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16726309T DK3303329T3 (da) 2015-06-02 2016-05-31 Fremgangsmåder til fremstilling af indazolderivater

Country Status (22)

Country Link
US (1) US10266525B2 (da)
EP (1) EP3303329B1 (da)
JP (1) JP6389967B2 (da)
KR (1) KR20180011115A (da)
CN (1) CN107660204B (da)
AU (1) AU2016273752B2 (da)
BR (1) BR112017023486B1 (da)
CA (1) CA2983966A1 (da)
CY (1) CY1122343T1 (da)
DK (1) DK3303329T3 (da)
ES (1) ES2760571T3 (da)
GB (1) GB201509492D0 (da)
HR (1) HRP20192117T1 (da)
HU (1) HUE047523T2 (da)
ME (1) ME03653B (da)
PL (1) PL3303329T3 (da)
PT (1) PT3303329T (da)
RS (1) RS59639B1 (da)
RU (1) RU2017134467A (da)
SI (1) SI3303329T1 (da)
SM (1) SMT201900705T1 (da)
WO (1) WO2016193255A1 (da)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53830B1 (sr) * 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
HRP20151017T1 (hr) * 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
EP2613781B1 (en) * 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
GB201018124D0 (en) * 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP3057588A1 (en) * 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease

Also Published As

Publication number Publication date
PL3303329T3 (pl) 2020-03-31
EP3303329B1 (en) 2019-09-18
RU2017134467A (ru) 2019-07-15
HRP20192117T1 (hr) 2020-02-21
BR112017023486A2 (en) 2018-07-24
CY1122343T1 (el) 2021-01-27
HUE047523T2 (hu) 2020-04-28
RU2017134467A3 (da) 2019-10-11
RS59639B1 (sr) 2020-01-31
US20180155334A1 (en) 2018-06-07
CN107660204A (zh) 2018-02-02
WO2016193255A1 (en) 2016-12-08
AU2016273752A1 (en) 2017-10-19
PT3303329T (pt) 2019-12-16
EP3303329A1 (en) 2018-04-11
SMT201900705T1 (it) 2020-01-14
JP6389967B2 (ja) 2018-09-12
SI3303329T1 (sl) 2020-02-28
AU2016273752B2 (en) 2018-07-05
US10266525B2 (en) 2019-04-23
ES2760571T3 (es) 2020-05-14
ME03653B (me) 2020-07-20
JP2018518477A (ja) 2018-07-12
CN107660204B (zh) 2021-04-13
BR112017023486B1 (pt) 2023-02-14
GB201509492D0 (en) 2015-07-15
CA2983966A1 (en) 2016-12-08
KR20180011115A (ko) 2018-01-31

Similar Documents

Publication Publication Date Title
IL261271A (en) Methods for making l-glufosinate
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3303618T3 (da) Fremgangsmåder til prognose af prostatacancer
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3376923T3 (da) Fremgangsmåde til tilberedning af en drik
DK3105220T3 (da) Fremgangsmåde til fremstilling af pyrimidinsulfamidderivater
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
LT3371168T (lt) Indolin-2-ono dariniai
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
HRP20190583T1 (hr) Postupci za pripremu spoja diariltiohidantoina
DK3166855T3 (da) Fremgangsmåde for tilvejebringelse af foldelinjer
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3418273T3 (da) Derivater af flavagliner
DK3231790T3 (da) Fremgangsmåde til fremstilling af kationisk lipid
DK3302788T3 (da) Fremgangsmåde til fremstilling af en sorbent
DK3302786T3 (da) Fremgangsmåde til fremstilling af en sorbent
HUE046518T2 (hu) Cikloalkilcsoporthoz kapcsolt diheterociklusos származékok
DK3507282T3 (da) Fremgangsmåde til fremstilling af indolcarboxamidforbindelser